TY - JOUR
T1 - Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
AU - Luengo, Alba
AU - Abbott, Keene L.
AU - Davidson, Shawn M.
AU - Hosios, Aaron M.
AU - Faubert, Brandon
AU - Chan, Sze Ham
AU - Freinkman, Elizaveta
AU - Zacharias, Lauren G.
AU - Mathews, Thomas P.
AU - Clish, Clary B.
AU - DeBerardinis, Ralph J.
AU - Lewis, Caroline A.
AU - Vander Heiden, Matthew G.
N1 - Funding Information:
We thank all members of the Vander Heiden lab, Isaac Harris, and Robert J. Downey for thoughtful discussion and advice. We also thank Genya Frenkel and Kendall Condon for assistance with the hypoxia experiment and Lukas Murmann for help with linear algebra. This work was supported by the Ludwig Center for Molecular Oncology Fund (A.L.), NSF GRFP DGE-1122374 (A.L.; K.L.A.; S.M.D.) and T32GM007287 (A.L.; K.L.A.; S.M.D.; A.M.H). E.F. was supported by United States Department of Defense Peer-Reviewed Medical Research Program grant W81XWH-15-1. R.J.D. acknowledges support from the Howard Hughes Medical Institute, a Cancer Prevention and Research Institute of Texas RP160089, and the National Cancer Institute (R35CA220449). M.G.V.H. acknowledges support from a Faculty Scholar grant from the Howard Hughes Medical Institute, SU2C, the Lustgarten Foundation, the MIT Center for Precision Cancer Medicine, the Ludwig Center at MIT, and the NIH (R01CA201276, R01CA168653, and P30CA14051).
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Increased glucose uptake and metabolism is a prominent phenotype of most cancers, but efforts to clinically target this metabolic alteration have been challenging. Here, we present evidence that lactoylglutathione (LGSH), a byproduct of methylglyoxal detoxification, is elevated in both human and murine non-small cell lung cancers (NSCLC). Methylglyoxal is a reactive metabolite byproduct of glycolysis that reacts non-enzymatically with nucleophiles in cells, including basic amino acids, and reduces cellular fitness. Detoxification of methylglyoxal requires reduced glutathione (GSH), which accumulates to high levels in NSCLC relative to normal lung. Ablation of the methylglyoxal detoxification enzyme glyoxalase I (Glo1) potentiates methylglyoxal sensitivity and reduces tumor growth in mice, arguing that targeting pathways involved in detoxification of reactive metabolites is an approach to exploit the consequences of increased glucose metabolism in cancer.
AB - Increased glucose uptake and metabolism is a prominent phenotype of most cancers, but efforts to clinically target this metabolic alteration have been challenging. Here, we present evidence that lactoylglutathione (LGSH), a byproduct of methylglyoxal detoxification, is elevated in both human and murine non-small cell lung cancers (NSCLC). Methylglyoxal is a reactive metabolite byproduct of glycolysis that reacts non-enzymatically with nucleophiles in cells, including basic amino acids, and reduces cellular fitness. Detoxification of methylglyoxal requires reduced glutathione (GSH), which accumulates to high levels in NSCLC relative to normal lung. Ablation of the methylglyoxal detoxification enzyme glyoxalase I (Glo1) potentiates methylglyoxal sensitivity and reduces tumor growth in mice, arguing that targeting pathways involved in detoxification of reactive metabolites is an approach to exploit the consequences of increased glucose metabolism in cancer.
UR - http://www.scopus.com/inward/record.url?scp=85076145094&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076145094&partnerID=8YFLogxK
U2 - 10.1038/s41467-019-13419-4
DO - 10.1038/s41467-019-13419-4
M3 - Article
C2 - 31811141
AN - SCOPUS:85076145094
SN - 2041-1723
VL - 10
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 5604
ER -
